Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Propofol for treatment resistant depression: A randomized controlled trial

Scott C. Tadler, Keith G. Jones, Carter Lybbert, Jason C. Huang, Rana Jawish, Daniela Solzbacher, E. Jeremy Kendrick, Matthew D. Pierson, Kamile Weischedel, Noreen Rana, Rebecca Jacobs, Lily C. Vonesh, Daniel A. Feldman, Claire Larson, Nathan Hoffman, Jacob E. Jessop, Adam L. Larson, Norman E. Taylor, David H. Odell, Kai Kuck, Brian J. Mickey
doi: https://doi.org/10.1101/2023.09.12.23294678
Scott C. Tadler
1Department of Anesthesiology, University of Utah
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: scott.tadler{at}hsc.utah.edu brian.mickey{at}utah.edu
Keith G. Jones
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
3Interdepartmental Program in Neuroscience, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carter Lybbert
4Department of Biomedical Engineering, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason C. Huang
4Department of Biomedical Engineering, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rana Jawish
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Solzbacher
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Jeremy Kendrick
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew D. Pierson
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamile Weischedel
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noreen Rana
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Jacobs
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lily C. Vonesh
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel A. Feldman
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
4Department of Biomedical Engineering, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Larson
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan Hoffman
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob E. Jessop
1Department of Anesthesiology, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam L. Larson
1Department of Anesthesiology, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman E. Taylor
1Department of Anesthesiology, University of Utah
3Interdepartmental Program in Neuroscience, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Odell
1Department of Anesthesiology, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Kuck
1Department of Anesthesiology, University of Utah
4Department of Biomedical Engineering, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Mickey
1Department of Anesthesiology, University of Utah
2Department of Psychiatry and Huntsman Mental Health Institute, University of Utah
3Interdepartmental Program in Neuroscience, University of Utah
4Department of Biomedical Engineering, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: scott.tadler{at}hsc.utah.edu brian.mickey{at}utah.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Anesthetic agents including ketamine and nitrous oxide have shown antidepressant properties when appropriately dosed. Our recent open-label trial of propofol, an intravenous anesthetic known to elicit transient positive mood effects, suggested that it may also produce robust and durable antidepressant effects when administered at a high dose that elicits an electroencephalographic (EEG) burst-suppression state. Here we report findings from a randomized controlled trial (NCT03684447) that compared two doses of propofol. We hypothesized greater improvement with a high dose that evoked burst suppression versus a low dose that did not.

Methods Participants with moderate-to-severe, treatment-resistant depression were randomized to a series of 6 treatments at low versus high dose (n=12 per group). Propofol infusions were guided by real-time processed frontal EEG to achieve predetermined pharmacodynamic criteria. The primary and secondary depression outcome measures were the 24-item Hamilton Depression Rating Scale (HDRS-24) and the Patient Health Questionnaire (PHQ-9), respectively. Secondary scales measured suicidal ideation, anxiety, functional impairment, and quality of life.

Results Treatments were well tolerated and blinding procedures were effective. The mean [95%-CI] change in HDRS-24 score was −5.3 [−10.3, −0.2] for the low-dose group and −9.3 [−12.9, −5.6] for the high-dose group (17% versus 33% reduction). The between-group effect size (standardized mean difference) was −0.56 [−1.39, 0.28]. The group difference was not statistically significant (p=0.24, linear model). The mean change in PHQ-9 score was −2.0 [−3.9, −0.1] for the low dose and −4.8 [−7.7, −2.0] for the high dose. The between-group effect size was −0.73 [−1.59, 0.14] (p=0.09). Secondary outcomes favored the high dose (effect sizes magnitudes 0.1 - 0.9) but did not generally reach statistical significance (p>0.05).

Conclusions The medium-sized effects observed between doses in this small, controlled, clinical trial suggest that propofol may have dose-dependent antidepressant effects. The findings also provide guidance for subsequent trials. A larger sample size and additional treatments in series are likely to enhance the ability to detect dose-dependent effects. Future work is warranted to investigate potential antidepressant mechanisms and dose optimization.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT03684447

Funding Statement

Supported by a gift from Peter Huntsman, the Huntsman Mental Health Institute, a Research Instrumentation Fund grant from the University of Utah Vice President for Research, and the University of Utah Clinical & Translational Science Institute (UL1TR002538)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research was approved by the University of Utah Institutional Review Board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Funding: Supported by a gift from Peter Huntsman, the Huntsman Mental Health Institute, a Research Instrumentation Fund grant from the University of Utah Vice President for Research, and the University of Utah Clinical & Translational Science Institute (UL1TR002538)

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 15, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Propofol for treatment resistant depression: A randomized controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Propofol for treatment resistant depression: A randomized controlled trial
Scott C. Tadler, Keith G. Jones, Carter Lybbert, Jason C. Huang, Rana Jawish, Daniela Solzbacher, E. Jeremy Kendrick, Matthew D. Pierson, Kamile Weischedel, Noreen Rana, Rebecca Jacobs, Lily C. Vonesh, Daniel A. Feldman, Claire Larson, Nathan Hoffman, Jacob E. Jessop, Adam L. Larson, Norman E. Taylor, David H. Odell, Kai Kuck, Brian J. Mickey
medRxiv 2023.09.12.23294678; doi: https://doi.org/10.1101/2023.09.12.23294678
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Propofol for treatment resistant depression: A randomized controlled trial
Scott C. Tadler, Keith G. Jones, Carter Lybbert, Jason C. Huang, Rana Jawish, Daniela Solzbacher, E. Jeremy Kendrick, Matthew D. Pierson, Kamile Weischedel, Noreen Rana, Rebecca Jacobs, Lily C. Vonesh, Daniel A. Feldman, Claire Larson, Nathan Hoffman, Jacob E. Jessop, Adam L. Larson, Norman E. Taylor, David H. Odell, Kai Kuck, Brian J. Mickey
medRxiv 2023.09.12.23294678; doi: https://doi.org/10.1101/2023.09.12.23294678

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Psychiatry and Clinical Psychology
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)